Rosetta Genomics' (ROSG) shares are +9% after saying that its Cancer Origin Test is being covered by Highmark Health Services, the fourth largest U.S. Blue Cross and Blue Shield-Affiliated company.
Highmark has 5.3M members in Pennsylvania, Delaware and West Virginia. The test is now available to one in five people in the U.S.
The product tests for the origin of tumors in Cancer of Unknown or Uncertain Primary (CUP). (PR)